403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Vor Bio To Participate In The 46Th Annual TD Cowen Health Care Conference
(MENAFN- GlobeNewsWire - Nasdaq) BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston, MA.
Presentation: Monday, March 2, 2026 at 9:50am – 10:20 am ET
Location: Regis
A live webcast and archived replay of the presentation will be remain available for a period of 90 days on the Company's website at:
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit .
Media & Investor Contacts:
Carl Mauch
...
Sarah Spencer
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment